19 June 2013
Keywords: tercica, increlex, gets, eu, od, status, primary
Article | 05 June 2006
California, USA-based Tercica, a biopharmaceutical company focused on the development of products for the endocrine health market, says that
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 June 2006
18 June 2013
© 2013 thepharmaletter.com